Literature DB >> 11134235

A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases.

P de Lonlay1, N Seta, S Barrot, B Chabrol, V Drouin, B M Gabriel, H Journel, M Kretz, J Laurent, M Le Merrer, A Leroy, D Pedespan, P Sarda, N Villeneuve, J Schmitz, E van Schaftingen, G Matthijs, J Jaeken, C Korner, A Munnich, J M Saudubray, V Cormier-Daire.   

Abstract

INTRODUCTION: Congenital disorders of glycosylation (CDG), or carbohydrate deficient glycoprotein syndromes, form a new group of multisystem disorders characterised by defective glycoprotein biosynthesis, ascribed to various biochemical mechanisms.
METHODS: We report the clinical, biological, and molecular analysis of 26 CDG I patients, including 20 CDG Ia, two CDG Ib, one CDG Ic, and three CDG Ix, detected by western blotting and isoelectric focusing of serum transferrin.
RESULTS: Based on the clinical features, CDG Ia could be split into two subtypes: a neurological form with psychomotor retardation, strabismus, cerebellar hypoplasia, and retinitis pigmentosa (n=11), and a multivisceral form with neurological and extraneurological manifestations including liver, cardiac, renal, or gastrointestinal involvement (n=9). Interestingly, dysmorphic features, inverted nipples, cerebellar hypoplasia, and abnormal subcutaneous fat distribution were not consistently observed in CDG Ia. By contrast, the two CDG Ib patients had severe liver disease, enteropathy, and hyperinsulinaemic hypoglycaemia but no neurological involvement. Finally, the CDG Ic patient and one of the CDG Ix patients had psychomotor retardation and seizures. The other CDG Ix patients had severe proximal tubulopathy, bilateral cataract, and white matter abnormalities (one patient), or multiorgan failure and multiple birth defects (one patient).
CONCLUSIONS: Owing to the remarkable clinical variability of CDG, this novel disease probably remains largely underdiagnosed. The successful treatment of CDG Ib patients with oral mannose emphasises the paramount importance of early diagnosis of PMI deficiency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11134235      PMCID: PMC1734729          DOI: 10.1136/jmg.38.1.14

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  28 in total

1.  Complex functional and structural coagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome type I.

Authors:  H Stibler; U Holzbach; L Tengborn; B Kristiansson
Journal:  Blood Coagul Fibrinolysis       Date:  1996-03       Impact factor: 1.276

2.  Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie.

Authors:  T Imbach; B Schenk; E Schollen; P Burda; A Stutz; S Grunewald; N M Bailie; M D King; J Jaeken; G Matthijs; E G Berger; M Aebi; T Hennet
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

3.  Early manifestations of the carbohydrate-deficient glycoprotein syndrome.

Authors:  M B Petersen; K Brostrøm; H Stibler; F Skovby
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

Review 4.  The carbohydrate-deficient glycoprotein syndromes: pre-Golgi and Golgi disorders?

Authors:  J Jaeken; H Carchon; H Stibler
Journal:  Glycobiology       Date:  1993-10       Impact factor: 4.313

5.  Carbohydrate-deficient glycoprotein syndrome type II.

Authors:  J Jaeken; P De Cock; H Stibler; C Van Geet; J Kint; V Ramaekers; H Carchon
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Carbohydrate-deficient glycoprotein syndrome with previously unreported features.

Authors:  F Eyskens; C Ceuterick; J J Martin; G Janssens; J Jaeken
Journal:  Acta Paediatr       Date:  1994-08       Impact factor: 2.299

7.  Hyperinsulinemic hypoglycemia as a presenting sign in phosphomannose isomerase deficiency: A new manifestation of carbohydrate-deficient glycoprotein syndrome treatable with mannose.

Authors:  P de Lonlay; M Cuer; S Vuillaumier-Barrot; G Beaune; P Castelnau; M Kretz; G Durand; J M Saudubray; N Seta
Journal:  J Pediatr       Date:  1999-09       Impact factor: 4.406

8.  Carbohydrate deficient glycoprotein syndrome type II: a deficiency in Golgi localised N-acetyl-glucosaminyltransferase II.

Authors:  J Jaeken; H Schachter; H Carchon; P De Cock; B Coddeville; G Spik
Journal:  Arch Dis Child       Date:  1994-08       Impact factor: 3.791

9.  Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I.

Authors:  E Van Schaftingen; J Jaeken
Journal:  FEBS Lett       Date:  1995-12-27       Impact factor: 4.124

10.  Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts.

Authors:  K Panneerselvam; H H Freeze
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

View more
  52 in total

1.  The clinical relevance of glycobiology.

Authors:  H Schachter
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

2.  Biochemical and molecular studies in 26 Spanish patients with congenital disorder of glycosylation type Ia.

Authors:  P Briones; M A Vilaseca; E Schollen; I Ferrer; M Maties; C Busquets; R Artuch; L Gort; M Marco; E van Schaftingen; G Matthijs; J Jaeken; A Chabás
Journal:  J Inherit Metab Dis       Date:  2002-12       Impact factor: 4.982

Review 3.  Neonatal congenital microvillus atrophy.

Authors:  N Pecache; S Patole; R Hagan; D Hill; A Charles; J M Papadimitriou
Journal:  Postgrad Med J       Date:  2004-02       Impact factor: 2.401

4.  Neurology of inherited glycosylation disorders.

Authors:  Hudson H Freeze; Erik A Eklund; Bobby G Ng; Marc C Patterson
Journal:  Lancet Neurol       Date:  2012-05       Impact factor: 44.182

5.  Congenital disorder of glycosylation type Ia presenting with hydrops fetalis.

Authors:  J M van de Kamp; D J Lefeber; G J G Ruijter; S J Steggerda; N S den Hollander; S M Willems; G Matthijs; B J H M Poorthuis; R A Wevers
Journal:  J Med Genet       Date:  2006-12-08       Impact factor: 6.318

6.  Early fatal course in siblings with CDG-Ia (caused by two novel mutations in the PMM2 gene): clinical, molecular and autopsy findings.

Authors:  Donald Wurm; Andrea Hänsgen; Yoo-Jin Kim; Angelika Lindinger; Ali Baghai; Ludwig Gortner
Journal:  Eur J Pediatr       Date:  2006-08-29       Impact factor: 3.183

7.  Congenital disorders of glycosylation type I: a rare but new cause of hyperechoic kidneys in infants and children due to early microcystic changes.

Authors:  Lucie Hertz-Pannier; Michele Déchaux; Martine Sinico; Sophie Emond; Valerie Cormier-Daire; Jean-Marie Saudubray; Francis Brunelle; Patrick Niaudet; Nathalie Seta; Pascale de Lonlay
Journal:  Pediatr Radiol       Date:  2005-11-22

Review 8.  Long-standing mild hypertransaminasaemia caused by congenital disorder of glycosylation (CDG) type IIx.

Authors:  P L Calvo; S Pagliardini; M Baldi; A Pucci; L Sturiale; D Garozzo; T Vinciguerra; C Barbera; J Jaeken
Journal:  J Inherit Metab Dis       Date:  2008-12-09       Impact factor: 4.982

Review 9.  Recognizable phenotypes in CDG.

Authors:  Carlos R Ferreira; Ruqaia Altassan; Dorinda Marques-Da-Silva; Rita Francisco; Jaak Jaeken; Eva Morava
Journal:  J Inherit Metab Dis       Date:  2018-04-13       Impact factor: 4.982

Review 10.  Cardiac complications of congenital disorders of glycosylation (CDG): a systematic review of the literature.

Authors:  D Marques-da-Silva; R Francisco; D Webster; V Dos Reis Ferreira; J Jaeken; T Pulinilkunnil
Journal:  J Inherit Metab Dis       Date:  2017-07-19       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.